Piqray
Novartis’ Piqray combo becomes first Europe-approved therapy for PIK3CA-mutated advanced breast cancer
July 29, 2020Research and Development, Sales and Marketing Europe, Novartis, Piqray, breast cancer, pharma
The European Commission (EC) has awarded its approval for Novartis’ Piqray (alpelisib) to be made available in combination with fulvestrant …
FDA approves first therapy PIK3CA-mutated HR+/HER2- advanced breast cancer
May 28, 2019Manufacturing and Production, Sales and Marketing Cancer, FDA, Novartis, Piqray, breast cancer, fulvestrant, pharma
Novartis’ Piqray (alpelisib) has secured approval from the FDA in combination with AstraZeneca’s Faslodex (fulvestrant) for the treatment of hormone …
Latest content
MedPharm appoints Jason Mieding as chief operating officer
November 8, 2026
Coriolis Pharma appoints Teun van der Heide as CEO
November 7, 2026
The evidence bar impacting UK medical cannabis access
November 6, 2026
